Tumores Ginecológicos

Estudo de coorte retrospectiva | Detecção de câncer ovariano em mulheres de risco médio: lesões anexiais de aparência clássica vs. não clássica.

31 Mai, 2022 | 12:11h

Ovarian Cancer Detection in Average-Risk Women: Classic- versus Nonclassic-appearing Adnexal Lesions at US – Radiology

Comunicado de imprensa: Researchers use ultrasound to predict ovarian cancer – Radiological Society of North America

Comentário: Appearance of Ovarian Lesions on Ultrasound May Predict Malignancy – HealthDay

 

Comentário no Twitter

Classifying adnexal lesion appearance as classic or nonclassic has high sensitivity and specificity for diagnosing malignancy in women at average risk for ovarian cancer. @BaranLab @drantil7 @kpatellippmann @katematuren @ayakamaya @hanna_zrad @LizSadowski https://t.co/6NphOIycMe pic.twitter.com/99DyWIHXwU

— Radiology (@radiology_rsna) March 28, 2022

 

---

Posicionamento científico | Implementação de teste para BRCA preventivo e preditivo em pacientes com cânceres de mama, ovário, pâncreas e próstata.

27 Mai, 2022 | 13:29h

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies – ESMO Open

---

Estudo randomizado fase 1/2 | Segurança e eficácia do inibidor mTOR (vistusertibe) combinado com anastrazol em pacientes com câncer endometrial metastático ou positivo para receptor hormonal.

27 Mai, 2022 | 13:22h

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

Endocrine therapy is used in clinical practice in the management of relapsed or advanced HR + endometrial cancer. Anastrozole + vistusertib demonstrated clinically significant improvement with manageable adverse events, encouraging further research https://t.co/hHDtloSdNs #GynCSM

— JAMA Oncology (@JAMAOnc) May 12, 2022

 

---

Revisão | Desfechos de Enhanced Recovery after Surgery (ERAS) na ginecologia oncológica.

10 Mai, 2022 | 12:11h

Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review – Current Oncology

---

Revisão | Avanços na radioterapia para tratamento do câncer de colo do útero.

10 Mai, 2022 | 12:09h

Advances in Radiation Oncology for the Treatment of Cervical Cancer – Current Oncology

---

Estudo randomizado | Imiquimod tópico vs. cirurgia para neoplasia intraepitelial vulvar.

4 Mai, 2022 | 13:31h

Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial – The Lancet (link para o resumo – $ para o texto completo)

---

Estudo randomizado | Manutenção da terapia com fuzuloparibe em pacientes com carcinoma ovariano recorrente e sensível a platina.

21 Abr, 2022 | 11:59h

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

---

Teste avançado para detectar infecção por papilomavírus humano melhora a avaliação prognóstica do câncer de colo do útero.

19 Abr, 2022 | 12:09h

Human Papillomavirus Infection Determines Prognosis in Cervical Cancer – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Editorial: Testing for High-Risk Human Papillomavirus in Lower Genital Tract Tumors: If Knowledge Does Not Translate to an Action That Helps Patients—Why Do It? – Journal of Clinical Oncology

Comentário: Study Confirms Favorable Prognosis for HPV-Positive Cervical Cancer— RNA sequencing identified more HPV+ tumors, showed 43% mortality disparity for HPV- tumors – MedPage Today (necessário cadastro gratuito)

---

Estudo randomizado | Rucaparibe vs. quimioterapia padrão em pacientes com câncer de ovário recidivante e mutação deletéria em BRCA1 ou BRCA2.

8 Abr, 2022 | 16:47h

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentário: ARIEL4 Trial: Rucaparib vs Chemotherapy in Patients With Relapsed Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations – The ASCO Post

 

Comentário no Twitter

In ARIEL4 phase III trial, pts with BRCA1/2-mut ovarian cancer who received ≥2 chemo regimens received rucaparib or chemo. In the ITT, mPFS was 7.4 mo vs 5.7 mo (HR 0.67, 95% CI 0.52–0.86; P = 0.0017). Three treatment-related deaths occurred w rucaparib https://t.co/G7j7djp6kV

— NatureRevClinOncol (@NatRevClinOncol) March 22, 2022

 

---

Estudo de coorte | Associação de linfedema de membro inferior com função física e atividades de vida diária entre idosos sobreviventes de câncer colorretal, endometrial e ovariano.

29 Mar, 2022 | 13:53h

Association of Lower Extremity Lymphedema With Physical Functioning and Activities of Daily Living Among Older Survivors of Colorectal, Endometrial, and Ovarian Cancer – JAMA Network Open

Comentários:

Older female cancer survivors face challenges with physical activity due to chronic lower extremity lymphedema – News Medical

Lower-Extremity Lymphedema Common in Older, Female Cancer Survivors – HealthDay

 

Comentário no Twitter

Cohort study found nearly 1/3 of older female survivors of #ColorectalCancer, #EndometrialCancer, or #OvarianCancer have lower-extremity lymphedema (LEL), which is associated with worse physical function and needing assistance with ADLs. https://t.co/806Tt88TuV

— JAMA Network Open (@JAMANetworkOpen) March 9, 2022

 

---